I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”
PALO ALTO, Calif., Dec. 21, 2022 — I Peace, Inc. has been awarded a “Special Recognition in Cell Therapy” during BioSpectrum Asia Excellence Award 2022 ceremony held in Singapore on December 2.
I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette. I Peace supports research institutions and pharmaceutical companies around the globe by providing clinical-grade iPSCs conforming with regulatory standards both in the U.S. and Japan. [Read more…]
iPSirius Wins $2M Award from European Innovation Council to Develop a Novel Stem Cell Vaccine to Help Cancer Patients Worldwide
iPSirius is creating a new frontier in stem cell-based cancer therapeutics by developing a vaccine to fight aggressive tumors.
Paris, France, 19th December 2022 – iPSirius is a European immunotherapy company that is working to bring a new range of off-the-shelf vaccines to cancer patients worldwide to improve their prognosis and quality of life. iPSirius has developed a pipeline of engineered induced pluripotent stem cell (iPS) vaccines using its proprietary iPVAC technology. [Read more…]
PeptiGrowth Inc. is Launching Novel Synthetic Peptides BMP7 selective inhibitor and BMP4 selective inhibitor
December 12th, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed two novel synthetic peptides, “BMP7 selective inhibitor (product code: PG-005)” and “BMP4 selective inhibitor (product code: PG-006)”, which selectively bind and inhibit BMP7 and BMP4 respectively. We started marketing this product on December 8th, 2022. [Read more…]
Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human Pluripotent Stem Cells
MINNEAPOLIS, Nov. 17, 2022 — Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and transISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells (hPSCs) that maximizes the viability of the cells using the Namocell Single Cell Dispenser. [Read more…]
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 119
- Next Page »